Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C25H29N3O3 |
| Molecular Weight | 419.5161 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)(CCN1C(=O)NC2=C1C=CC=C2)NCC(O)COC3=C4C=CC=CC4=CC=C3
InChI
InChIKey=YWRIUGFSIQMHJK-UHFFFAOYSA-N
InChI=1S/C25H29N3O3/c1-25(2,14-15-28-22-12-6-5-11-21(22)27-24(28)30)26-16-19(29)17-31-23-13-7-9-18-8-3-4-10-20(18)23/h3-13,19,26,29H,14-17H2,1-2H3,(H,27,30)
| Molecular Formula | C25H29N3O3 |
| Molecular Weight | 419.5161 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Adimolol is an antihypertensive agent with a potent antagonist of central beta-adrenoceptors and has a weaker alpha 1-adrenolytic action. The central alpha 2-antagonistic effect is either very weak or absent. The reduction in beta-adrenoceptor number following adimolol suggests that this prolonged effect may not be solely due to competitive antagonism but may additionally depend upon non-competitive antagonism at beta-adrenoceptors. Adimolol reduced supine, standing and exercise heart rates in a dose dependent manner.
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 09:09:23 GMT 2025
by
admin
on
Wed Apr 02 09:09:23 GMT 2025
|
| Record UNII |
B6CJY5K2ST
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29576
Created by
admin on Wed Apr 02 09:09:23 GMT 2025 , Edited by admin on Wed Apr 02 09:09:23 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
100000087701
Created by
admin on Wed Apr 02 09:09:23 GMT 2025 , Edited by admin on Wed Apr 02 09:09:23 GMT 2025
|
PRIMARY | |||
|
B6CJY5K2ST
Created by
admin on Wed Apr 02 09:09:23 GMT 2025 , Edited by admin on Wed Apr 02 09:09:23 GMT 2025
|
PRIMARY | |||
|
CHEMBL1742448
Created by
admin on Wed Apr 02 09:09:23 GMT 2025 , Edited by admin on Wed Apr 02 09:09:23 GMT 2025
|
PRIMARY | |||
|
71227
Created by
admin on Wed Apr 02 09:09:23 GMT 2025 , Edited by admin on Wed Apr 02 09:09:23 GMT 2025
|
PRIMARY | |||
|
DTXSID00868480
Created by
admin on Wed Apr 02 09:09:23 GMT 2025 , Edited by admin on Wed Apr 02 09:09:23 GMT 2025
|
PRIMARY | |||
|
78459-19-5
Created by
admin on Wed Apr 02 09:09:23 GMT 2025 , Edited by admin on Wed Apr 02 09:09:23 GMT 2025
|
PRIMARY | |||
|
C73013
Created by
admin on Wed Apr 02 09:09:23 GMT 2025 , Edited by admin on Wed Apr 02 09:09:23 GMT 2025
|
PRIMARY | |||
|
ADIMOLOL
Created by
admin on Wed Apr 02 09:09:23 GMT 2025 , Edited by admin on Wed Apr 02 09:09:23 GMT 2025
|
PRIMARY | |||
|
SUB05270MIG
Created by
admin on Wed Apr 02 09:09:23 GMT 2025 , Edited by admin on Wed Apr 02 09:09:23 GMT 2025
|
PRIMARY | |||
|
C045342
Created by
admin on Wed Apr 02 09:09:23 GMT 2025 , Edited by admin on Wed Apr 02 09:09:23 GMT 2025
|
PRIMARY | |||
|
5327
Created by
admin on Wed Apr 02 09:09:23 GMT 2025 , Edited by admin on Wed Apr 02 09:09:23 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
|
ENANTIOMER -> RACEMATE | |||
|
|
TARGET -> INHIBITOR |
|
||
|
|
ENANTIOMER -> RACEMATE | |||
|
SALT/SOLVATE -> PARENT | |||
|
TARGET -> INHIBITOR |
may inhibit other alpha-1 receptors
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| Biological Half-life | PHARMACOKINETIC |
|
|
|||